{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T22:04:52Z","timestamp":1783116292159,"version":"3.54.6"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Quebec HIV Cohort"},{"DOI":"10.13039\/501100000156","name":"Fonds de la Recherche du Qu\u00e9bec en Sant\u00e9","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000156","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000156","name":"(FRQS)","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000156","id-type":"DOI","asserted-by":"crossref"}]},{"name":"R\u00e9seau SIDA-MI"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,6,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The impact of different therapeutic classes of drugs in antiretroviral therapy (ART) regimens on the CD4\/CD8 ratio is not well documented in people treated for HIV. The objective of this study was to analyze the long-term effect of exposure to integrase strand transfer inhibitor (INSTI) on CD4\/CD8 ratio compared with nonnucleoside reverse transcriptase inhibitor (NNRTI) or protease inhibitor (PI) among ART-treated persons with HIV (PWH).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Data from the Quebec HIV Cohort collected from 31 August 2017 were used. Our analysis included all patients in the cohort who received a first or subsequent ART regimen composed of 2 nucleoside reverse transcriptase inhibitors (NRTIs) and a third active drug of a different class (NNRTI, PI, or INSTI) for at least 16 weeks. Marginal structural Cox models were constructed to estimate the effect of different therapeutic classes on the CD4\/CD8 ratio outcome.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Among the 3907 eligible patients, 972 (24.9%), 1996 (51.1%), and 939 (24.0%) were exposed to an ART regimen whose third active agent was an NNRTI, PI, or INSTI, respectively. The total follow-up time was 13 640.24 person-years. The weighted hazard ratio for the association between the third active class and CD4\/CD8 ratio \u22651 was .56 (95% confidence interval [CI]: .48\u2013.65) for patients exposed to NNRTI + 2 NRTIs and .41 (95% CI: .35\u2013.47) for those exposed to PI + 2 NRTIs, compared with those exposed INSTI + 2 NRTIs.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>For people treated for HIV, INSTI-based ART appears to be associated with a higher CD4\/CD8 ratio than NNRTI and PI-based ART.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/cid\/ciad056","type":"journal-article","created":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T21:12:10Z","timestamp":1675285930000},"page":"1879-1888","source":"Crossref","is-referenced-by-count":4,"title":["CD4\/CD8 Ratio Outcome According to the Class of the Third Active Drug in Antiretroviral Therapy Regimens: Results From the Quebec Human Immunodeficiency Virus Cohort Study"],"prefix":"10.1093","volume":"76","author":[{"given":"Mohamed N\u2019dongo","family":"Sangar\u00e9","sequence":"first","affiliation":[{"name":"Universit\u00e9 du Qu\u00e9bec en Abitibi-T\u00e9miscamingue , Rouyn-Noranda , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Guy","family":"Baril","sequence":"additional","affiliation":[{"name":"Clinique de M\u00e9decine Urbaine du Quartier Latin , Montreal , Canada"},{"name":"Faculty of Medicine, Universit\u00e9 de Montr\u00e9al , Montreal , Canada"},{"name":"Centre Hospitalier de l\u2019Universit\u00e9 de Montr\u00e9al , Montreal , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"de Pokomandy","sequence":"additional","affiliation":[{"name":"Chronic Viral Illness Service, McGill University Health Centre , Montreal , Canada"},{"name":"Department of Family Medicine, McGill University , Montreal , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Klein","sequence":"additional","affiliation":[{"name":"Chronic Viral Illness Service, McGill University Health Centre , Montreal , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00e9jean","family":"Thomas","sequence":"additional","affiliation":[{"name":"Clinique M\u00e9dicale L'Actuel , Montreal , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9cile","family":"Tremblay","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Universit\u00e9 de Montr\u00e9al , Montreal , Canada"},{"name":"Centre Hospitalier de l\u2019Universit\u00e9 de Montr\u00e9al , Montreal , Canada"},{"name":"Department of Microbiology, Infectious Diseases, and Immunology, Universit\u00e9 de Montr\u00e9al , Montreal , Canada"},{"name":"Department of Microbiology and Immunology, Centre Hospitalier de l\u2019Universit\u00e9 de Montr\u00e9al , Montreal , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Costa","family":"Pexos","sequence":"additional","affiliation":[{"name":"Chronic Viral Illness Service, McGill University Health Centre , Montreal , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeleine","family":"Durand","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Infectious Diseases, and Immunology, Universit\u00e9 de Montr\u00e9al , Montreal , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seerat","family":"Chawla","sequence":"additional","affiliation":[{"name":"Department of Family Medicine, McGill University , Montreal , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Laporte","sequence":"additional","affiliation":[{"name":"Sainte Justine University Hospital Center, Montreal , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Trottier","sequence":"additional","affiliation":[{"name":"Sainte Justine University Hospital Center, Montreal , Canada"},{"name":"Department of Social and Preventive Medicine, Universit\u00e9 de Montr\u00e9al , Montreal , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,2,1]]},"reference":[{"key":"2023060818540081600_ciad056-B1","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1097\/QAD.0b013e32835faa72","article-title":"The CD4\/CD8 ratio as a marker T-cell activation, senescence and activation\/exhaustion in treated HIV-infected children and young adults","volume":"27","author":"Sainz","year":"2013","journal-title":"AIDS"},{"key":"2023060818540081600_ciad056-B2","doi-asserted-by":"crossref","first-page":"e77665","DOI":"10.1371\/journal.pone.0077665","article-title":"Predictors of CD4:cD8 ratio normalization and its effect on health outcomes in the era of combination antiretroviral therapy","volume":"8","author":"Leung","year":"2013","journal-title":"PLoS One"},{"key":"2023060818540081600_ciad056-B3","doi-asserted-by":"crossref","first-page":"e1004078","DOI":"10.1371\/journal.ppat.1004078","article-title":"HIV-infected individuals with low CD4\/CD8 ratio despite effective antiretroviral therapy exhibit altered T cell subsets, heightened CD8+ T cell activation, and increased risk of non-AIDS morbidity and mortality","volume":"10","author":"Serrano-Villar","year":"2014","journal-title":"PLoS Pathog"},{"key":"2023060818540081600_ciad056-B4","doi-asserted-by":"crossref","first-page":"302638","DOI":"10.1155\/2015\/302638","article-title":"Cardiovascular complications of HIV-associated immune dysfunction","volume":"2015","author":"Zaaqoq","year":"2015","journal-title":"Cardiol Res Pract"},{"key":"2023060818540081600_ciad056-B5","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1146\/annurev-med-042909-093756","article-title":"HIV Infection, inflammation, immunosenescence, and aging","volume":"62","author":"Deeks","year":"2011","journal-title":"Annu Rev Med"},{"key":"2023060818540081600_ciad056-B6","doi-asserted-by":"crossref","first-page":"5737","DOI":"10.1182\/blood-2009-02-204172","article-title":"Hodgkin lymphoma in the Swiss HIV cohort study","volume":"113","author":"Clifford","year":"2009","journal-title":"Blood"},{"key":"2023060818540081600_ciad056-B7","doi-asserted-by":"crossref","first-page":"e85798","DOI":"10.1371\/journal.pone.0085798","article-title":"Increased risk of serious non-AIDS-related events in HIV-infected subjects on antiretroviral therapy associated with a low CD4\/CD8 ratio","volume":"9","author":"Serrano-Villar","year":"2014","journal-title":"PLoS One"},{"issue":"4 Suppl 3","key":"2023060818540081600_ciad056-B8","doi-asserted-by":"crossref","first-page":"19723","DOI":"10.7448\/IAS.17.4.19723","article-title":"The CD4:CD8 ratio is associated with IMT progression in HIV-infected patients on antiretroviral treatment","volume":"17","author":"Bernal","year":"2014","journal-title":"J Int AIDS Soc"},{"key":"2023060818540081600_ciad056-B9","doi-asserted-by":"crossref","first-page":"e98","DOI":"10.1016\/S2352-3018(15)00006-5","article-title":"CD4\/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: an observational cohort study","volume":"2","author":"Mussini","year":"2015","journal-title":"Lancet HIV"},{"key":"2023060818540081600_ciad056-B10","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1111\/j.1469-0691.2011.03650.x","article-title":"Factors influencing the normalization of CD4+ T-cell count, percentage and CD4+\/CD8+ T-cell ratio in HIV-infected patients on long-term suppressive antiretroviral therapy","volume":"18","author":"Torti","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"2023060818540081600_ciad056-B11","author":"Castilho"},{"key":"2023060818540081600_ciad056-B12","author":"Moeng"},{"key":"2023060818540081600_ciad056-B13","author":"Achenbach"},{"key":"2023060818540081600_ciad056-B14","author":"Serrano-Villar"},{"key":"2023060818540081600_ciad056-B15","author":"Novak"},{"key":"2023060818540081600_ciad056-B16","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1097\/00002030-200305230-00010","article-title":"Cardiovascular disease risk factors in HIV patients\u2013association with antiretroviral therapy. Results from the DAD study","volume":"17","author":"Friis-M\u00f8ller","year":"2003","journal-title":"AIDS"},{"key":"2023060818540081600_ciad056-B17","first-page":"1","article-title":"Monitoring the CD4\/CD8 ratio: a promising indicator of disease progression in HIV-infected individuals?","volume":"10","author":"Serrano-Villar","year":"2015","journal-title":"Future Med"},{"key":"2023060818540081600_ciad056-B18","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1089\/aid.2014.0080","article-title":"Chronic inflammation in a long-term cohort of HIV-infected patients according to the normalization of the CD4:CD8 ratio","volume":"30","author":"Saracino","year":"2014","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"1\u20133","key":"2023060818540081600_ciad056-B19","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0165-2478(98)00159-X","article-title":"Restoration of the immune system with anti-retroviral therapy","volume":"66","author":"Autran","year":"1999","journal-title":"Immunol Lett"},{"key":"2023060818540081600_ciad056-B20","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/hiv.12081","article-title":"The CD4:CD8 ratio is associated with markers of age-associated disease in virally suppressed HIV-infected patients with immunological recovery","volume":"15","author":"Serrano-Villar","year":"2014","journal-title":"HIV Med"},{"key":"2023060818540081600_ciad056-B21","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/QAI.0000000000000286","article-title":"Factors associated with CD8+ T-cell activation in HIV-1-infected patients on long-term antiretroviral therapy","volume":"67","author":"Zheng","year":"2014","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2023060818540081600_ciad056-B22","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1128\/CDLI.5.6.755-761.1998","article-title":"Levels of cytokines and immune activation markers in plasma in human immunodeficiency virus infection: quality control procedures","volume":"5","author":"Aziz","year":"1998","journal-title":"Clin Diagn Lab Immunol"},{"key":"2023060818540081600_ciad056-B23","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1038\/nm1511","article-title":"Microbial translocation is a cause of systemic immune activation in chronic HIV infection","volume":"12","author":"Brenchley","year":"2006","journal-title":"Nat Med"},{"key":"2023060818540081600_ciad056-B24","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.phrs.2009.07.009","article-title":"Plasma concentrations of the cardiovascular risk factor asymmetric dimethylarginine (ADMA) are increased in patients with HIV-1 infection and correlate with immune activation markers","volume":"60","author":"Kurz","year":"2009","journal-title":"Pharmacol Res"},{"key":"2023060818540081600_ciad056-B25","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jinf.2012.09.013","article-title":"The CD4\/CD8 ratio in HIV-infected subjects is independently associated with T-cell activation despite long-term viral suppression","volume":"66","author":"Serrano-Villar","year":"2013","journal-title":"J Infect"},{"key":"2023060818540081600_ciad056-B26","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S2055-6640(20)30688-9","article-title":"Virological and immunological characteristics of HIV-infected individuals at the earliest stage of infection","volume":"2","author":"Ananworanich","year":"2016","journal-title":"J Virus Erad"},{"key":"2023060818540081600_ciad056-B27","doi-asserted-by":"crossref","first-page":"e94018","DOI":"10.1371\/journal.pone.0094018","article-title":"Delay in cART initiation results in persistent immune dysregulation and poor recovery of T-cell phenotype despite a decade of successful HIV suppression","volume":"9","author":"Ndumbi","year":"2014","journal-title":"PLoS One"},{"key":"2023060818540081600_ciad056-B28","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1093\/jac\/dkw375","article-title":"Different impact of raltegravir versus efavirenz on CD4\/CD8 ratio recovery in HIV-infected patients","volume":"72","author":"Serrano-Villar","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2023060818540081600_ciad056-B29","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1097\/QAD.0b013e328359f29c","article-title":"Changes in cardiovascular biomarkers in HIV-infected patients switching from ritonavir-boosted protease inhibitors to raltegravir","volume":"26","author":"Mart\u00ednez","year":"2012","journal-title":"AIDS"},{"key":"2023060818540081600_ciad056-B30","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1097\/QAI.0000000000002079","article-title":"Immunological and neurometabolite changes associated with switch from efavirenz to an integrase inhibitor","volume":"81","author":"Asundi","year":"2019","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2023060818540081600_ciad056-B31","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/QAI.0000000000002525","article-title":"Integrase inhibitors use and cytomegalovirus infection predict immune recovery in people living with HIV starting first-line therapy","volume":"86","author":"Fabbiani","year":"2021","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2023060818540081600_ciad056-B32","doi-asserted-by":"crossref","first-page":"e565","DOI":"10.1016\/S2352-3018(20)30202-2","article-title":"Effects of first-line antiretroviral therapy on the CD4\/CD8 ratio and CD8 cell counts in CoRIS: a prospective multicentre cohort study","volume":"7","author":"Serrano-Villar","year":"2020","journal-title":"Lancet HIV"},{"key":"2023060818540081600_ciad056-B33","doi-asserted-by":"crossref","first-page":"e0140519","DOI":"10.1371\/journal.pone.0140519","article-title":"Antiretroviral regimens and CD4\/CD8 ratio normalization in HIV-infected patients during the initial year of treatment: a cohort study","volume":"10","author":"De Salvador-Guillou\u00ebt","year":"2015","journal-title":"PLoS One"},{"key":"2023060818540081600_ciad056-B34","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1093\/jac\/dkaa024","article-title":"Impact of first-line antiretroviral therapy regimens on the restoration of the CD4\/CD8 ratio in the CNICS cohort","volume":"75","author":"Herrera","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"2023060818540081600_ciad056-B35","doi-asserted-by":"crossref","first-page":"e3108","DOI":"10.1097\/MD.0000000000003108","article-title":"Comparative impact of suppressive antiretroviral regimens on the CD4\/CD8 T-cell ratio: a cohort study","volume":"95","author":"Masi\u00e1","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"2023060818540081600_ciad056-B36","doi-asserted-by":"crossref","first-page":"e23335","DOI":"10.1097\/MD.0000000000023335","article-title":"Impact of previous HIV resistance and virologic failures on virologic outcome following a switch to dolutegravir with 2 NRTIs among people living with HIV","volume":"99","author":"Sangar\u00e9","year":"2020","journal-title":"Medicine (Baltimore)"},{"key":"2023060818540081600_ciad056-B37","doi-asserted-by":"crossref","first-page":"ofaa404","DOI":"10.1093\/ofid\/ofaa404","article-title":"Treatment switch to dolutegravir with 2 nucleoside reverse-transcriptase inhibitors (NRTI) in comparison to continuation with protease inhibitor\/ritonavir among patients with human immunodeficiency virus at risk for prior NRTI resistance: a cohort analysis of real-world data","volume":"7","author":"Sangar\u00e9","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"2023060818540081600_ciad056-B38","author":"Thomas","year":"2011"},{"key":"2023060818540081600_ciad056-B39","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1093\/aje\/kwv254","article-title":"Using Big Data to emulate a target trial when a randomized trial is not available","volume":"183","author":"Hern\u00e1n","year":"2016","journal-title":"Am J Epidemiol"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciad056\/49283017\/ciad056.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/76\/11\/1879\/50541603\/ciad056.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/76\/11\/1879\/50541603\/ciad056.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T18:54:44Z","timestamp":1686250484000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/76\/11\/1879\/7019415"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,1]]},"references-count":39,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,2,1]]},"published-print":{"date-parts":[[2023,6,8]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciad056","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,6,1]]},"published":{"date-parts":[[2023,2,1]]}}}